Germany's Fresenius Medical says Q3 results weighed by China; narrows forecast
Germany's Fresenius Medical says Q3 results weighed by China; narrows forecast
Overview
Germany kidney care provider's Q3 revenue rose 1% yr/yr, slightly beating analyst expectations
Net income and EPS declined sharply, mainly due to one-time China strategy costs
Company narrowed FY 2026 outlook to flat revenue and operating income growth between flat and negative mid-single digit
Outlook
Fresenius Medical Care expects 2026 revenue growth to be broadly flat versus prior year
Company narrows 2026 operating income outlook to between flat and a negative mid-single digit percent growth rate
Company cites anticipated headwinds in Q4 as reason for narrowing full-year outlook
Result Drivers
CARE DELIVERY GROWTH - Q3 revenue growth was driven by increases in Care Delivery and Care Enablement segments, offset by declines in Value-Based Care
CHINA STRATEGY COSTS - One-time costs related to the China strategy refinement weighed on net income and operating income
REGULATORY AND INFLATION HEADWINDS - Operating income fell due to regulatory changes and increased inflation, per CFO Martin Fischer
Company press release: ID:nPn7FpBF6a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Slight Beat* | EUR 4.94 bln | EUR 4.91 bln (8 Analysts) |
Q3 Net Income |
| EUR 160 mln |
|
Q3 Basic EPS |
| EUR 0.61 |
|
Q3 EBIT |
| EUR 384 mln |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 9 "hold" and 8 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Fresenius Medical Care AG is €42.00, about 3.7% above its November 2 closing price of €40.50
The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago
Reuters Recommended Reads
Nov 3 - Fresenius Medical cuts 2026 profit outlook as US treatment decline deepens
Nov 2 - Fresenius signs biosimilars pipeline agreement with WuXi Biologics
Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Fresenius Medical Care AG
See all newsFMC seen down as Fresenius cuts stake to 20%
Germany's Fresenius cuts FMC stake to 20%
Brief: Fresenius Investment In Fresenius Medical Care Reduced From Approximately 25% To Approximately 20% Of Issued Share Capital
Brief: Fresenius Medical Care AG ABB Orders Below Eur 39.00 Per Share, Says Book Runner
Brief: Bookrunner Says Fresenius Medical ABB C. 13.4 Mln Shares, Books Are Closed